The therapeutic options for influenza are limited due to the emergence of drug-resistant virus strains. The influenza virus glycoprotein hemagglutinin (HA) plays a critical role in virus infection. MBX2329 is a small-molecule inhibitor targeting HA-mediated viral entry. MBX2329 showed concentration-dependent inhibitory activity against HIV/HA(H5) with an IC90 value of 8.6μM. MBX2329 displayed little inhibitory activity against HIV/LASV-GP, HIV/EBOV-GP, and HIV/VSV-G with IC90 values above >100 μM. MBX2329 inhibited influenza A H1N1 virus strains A/PR/8/34 (H1N1), A/Florida/21/2008 (H1N1-H275Y), A/Washington/10/2008 (H1N1), and A/California/10/2009 (H1N1) with IC50 values of 0.29–0.53μM. It also inhibited HPAI H5N1 virus strain A/Hong Kong/H5N1 with an IC50 value of 5.9μM. MBX2329 inhibited acid-induced hemolysis in a concentration-dependent manner with an IC50 value of 2.1μM[3].
搜索
